NASDAQ:OSUR - OraSure Technologies Stock Price, Forecast & News

OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."

OraSure Technologies, Inc. (NASDAQ:OSUR) posted its quarterly earnings results on Wednesday, February, 19th. The medical instruments supplier reported $0.04 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.07 by $0.03. The medical instruments supplier earned $49.67 million during the quarter, compared to analyst estimates of $47.03 million. OraSure Technologies had a net margin of 10.77% and a return on equity of 2.72%. OraSure Technologies's revenue for the quarter was down 1.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.16 EPS. View OraSure Technologies' Earnings History.

OraSure Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for OraSure Technologies.

OraSure Technologies updated its FY 2020 After-Hours earnings guidance on Wednesday, February, 19th. The company provided earnings per share (EPS) guidance of -0.1--0.07 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.24. The company issued revenue guidance of $145-155 million, compared to the consensus revenue estimate of $170.8 million.

1 analysts have issued 12-month target prices for OraSure Technologies' stock. Their forecasts range from $8.00 to $8.00. On average, they expect OraSure Technologies' stock price to reach $8.00 in the next year. This suggests a possible upside of 32.2% from the stock's current price. View Analyst Price Targets for OraSure Technologies.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for OraSure Technologies.

News headlines about OSUR stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. OraSure Technologies earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave media stories about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for OraSure Technologies.

Some companies that are related to OraSure Technologies include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Cerus (CERS), Anika Therapeutics (ANIK), Antares Pharma (ATRS) and Utah Medical Products (UTMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other OraSure Technologies investors own include Merit Medical Systems (MMSI), Citigroup (C), XOMA (XOMA), Energy Transfer LP Unit (ET), Overstock.com (OSTK), Ford Motor (F), Celldex Therapeutics (CLDX), CBL & Associates Properties (CBL), Opko Health (OPK) and SandRidge Permian Trust (PER).

OraSure Technologies' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (6.79%), American Capital Management Inc. (5.12%), State Street Corp (4.17%), Bank of America Corp DE (1.79%), Bank of New York Mellon Corp (1.46%) and Geode Capital Management LLC (1.41%). Company insiders that own OraSure Technologies stock include Charles W Patrick, Jack E Jerrett, Roberto Cuca and Stephen S Phd Tang. View Institutional Ownership Trends for OraSure Technologies.

OSUR stock was sold by a variety of institutional investors in the last quarter, including Penn Capital Management Co. Inc., Renaissance Technologies LLC, Assenagon Asset Management S.A., Oxford Asset Management LLP, Marshall Wace LLP, Goldman Sachs Group Inc., Public Sector Pension Investment Board and Arizona State Retirement System. View Insider Buying and Selling for OraSure Technologies.

OSUR stock was purchased by a variety of institutional investors in the last quarter, including Bank of America Corp DE, UBS Group AG, Echo Street Capital Management LLC, Jacobs Levy Equity Management Inc., Acadian Asset Management LLC, ETRADE Capital Management LLC, Envestnet Asset Management Inc. and Earnest Partners LLC. Company insiders that have bought OraSure Technologies stock in the last two years include Jack E Jerrett, Roberto Cuca and Stephen S Phd Tang. View Insider Buying and Selling for OraSure Technologies.

Shares of OSUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OSUR stock can currently be purchased for approximately $6.05.

OraSure Technologies has a market capitalization of $373.44 million and generates $154.60 million in revenue each year. The medical instruments supplier earns $16.66 million in net income (profit) each year or $0.13 on an earnings per share basis. OraSure Technologies employs 398 workers across the globe.View Additional Information About OraSure Technologies.

The official website for OraSure Technologies is http://www.orasure.com/.

OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The medical instruments supplier can be reached via phone at 610-882-1820 or via email at [email protected]